Loading
A phase 2 trial of SYHX2008 injection in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) is a phase 2 interventional study registered as NCT06505395 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 90 participants planned, started 2024-07-30 and due to reach its primary completion in 2027-08-01. Interventions recorded: SYHX2008 injection and Sandostatin LAR@.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/